Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles

Parkinson's disease (PD), although being the second most prevalent neurodegenerative disease (ND) encounters lack of definitive treatment and challenges in drug delivery. There are enormous factors provoking degeneration of neurons in the substantia nigra of brain that leads to symptoms of Parkinson's, such as increase in oxidative stress, overexpression of α-synuclein, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure, and many...